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1. Introduction 
Patients receiving long-term anticoagulant and antiplatelet medications pose a clinical 
challenge when therapy needs intraocular surgery, including cataract surgery and 
vitrectomy [1-3]. Maintaining antiplatelet and anticoagulation places them at risk for serious 
bleeding complications, whereas discontinuing these medications puts them at risk of 
thromboembolic complications [4-6]. Currently, there is little consensus on the appropriate 
perioperative treatment of patients on long-term acetylsalicylic acid (aspirin) and warfarin 
therapy [7-9]. In this study, we compared the incidence of hemorrhagic and non-
hemorrhagic complications and visual course of phacoemulsification alone and combined 
phacoemulisification and vitrectomy between patients who maintained or discontinued 
anticoagulant and/or antiplatelet medications. 
2. Patients and methods 
A total of 824 consecutive cases of 532 patients undergoing cataract surgery alone and of 69 
consecutive cases of 69 patients undergoing combined cataract and vitreous surgery for the 
treatment of epiretinal membrane and macular hole who had been administered warfarin 
and/or aspirin for 6 months or longer between April 2005 and March 2009 were studied 
(Table 1). Before April 2007, all patients discontinued the drugs prior to the surgery. After 
 
 Anticoagulant and 
antiplatelet medications 
Number of patients 
(Number of cases) 
Phacoemulsification alone group Discontinuation subgroup 274 (421) 
Maintenance subgroup 258 (403) 
Combined phacoemulsification and 
vitrectomy group 
Discontinuation subgroup 33 (33) 
Maintenance subgroup 36 (36) 
Table 1. Outline of patients with discontinuation and maintenance of anticoagulant and/or 
antiplatelet medications  
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April 2007, all patients maintained the treatment at the time of surgery (Table 1). The 
discontinuation subgroups consisted of patients who ceased taking warfarin and/or aspirin 
1 week before the surgery, with their therapies then restarted 2 days postoperatively. The 
study protocol and consent forms were approved by the Human Subjects Committee. 
2.1 Surgical procedure and postoperative interventions 
Cataract surgery 
Phacoemulsification and intraocular lens implantation was performed through a superior 
sclerocorneal incision after scleral cauterization. Sub-Tenon anesthesia with 2% lidocaine 
(Xylocaine, Asteras, Tokyo, Japan) was employed using Fukasaku’s blunt subtenon’s 
cannula (Handaya, Tokyo, Japan). A standard phacoemulsification technique was used. In 
all cases, a three-piece hydrophobic acrylic intraocular lens (AcrySof™ MA30BM; Alcon, 
Fort Worth, TX, USA) was implanted. Sodium hyaluronate 1% (Healon, AMO, Santana, CA, 
USA) was used as viscoelastics. 
Vitrectomy for epiretinal membrane and macular hole 
A standard three port pars plana vitrectomy was performed in all patients after sub-Tenon 
anesthesia, phacoemulsification and intraocular lens implantation. We achieved a complete 
posterior vitreous detachment during pars plana vitrectomy using a vitreous cutter. For 
patients with epiretinal membrane, the membranes were removed with a slightly bent 
microvitreoretinal blade or internal limiting membrane forceps. For patients with macular 
hole, the internal limiting membranes around the macular hole were removed in assistance 
with triamcinolone acetonide or indocyanine green. Sulfur hexafluoride (20%) was used for 
gas tamponade. Patients remained in the prone position for 7-10 days postoperatively. 
Postoperative management 
In both groups, all patients were given topical levofloxacin, dexamethasone and diclofenac 
three times daily during the first 2 weeks, with the drugs then tapered off over the next 3 
months. 
Evaluation of outcomes 
Before enrollment, patients had an ocular and systemic history taken as well as slit-lamp 
biomicroscopy, visual acuity, a physical examination, and dilated fundoscopy. Best-
corrected visual acuity (BCVA) was measured, with the log of the minimum angle of 
resolution (LogMAR) then calculated and used for all statistical analyses. Intraocular 
pressure was measured using Goldmann applanation tonometry while a slit-lamp 
examination was used to clinically grade the preoperative nuclear sclerosis as per the 
method of Emery and Little [10]. After pupil dilation, ophthalmoscopic and slit-lamp 
biomicroscopic examinations were employed to assess retinal, vitreous and 
choroidal/suprachoroidal hemorrhages. For patients with epiretinal membrane and 
macular hole, we performed optical coherence tomography (OCT) scanning (OCT scanner 
3000 and Cirrus, Humphrey Instruments, San Leandro, California) before and 1, 3, and 6 
months after surgery. The fovea was identified as the patient’s fixation point or with the 
fundus monitor in the OCT device. The cross-sectional images were normalized and 
smoothed using OCT plug-in software. Patients were also assessed intraoperatively and at 
every postoperative visit for the presence of general complications, which included 
cerebral events such as transient ischemic attack and cerebral infarction and hemorrhage, 
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and cardiovascular events such as deep vein thrombosis, myocardial ischemia, and 
myocardial infarction. Hemorrhagic complications were defined as subconjunctival 
hemorrhage and hyphema, or retinal, vitreous and choroidal/suprachoroidal 
hemorrhage. Hypotony was defined as an intraocular pressure of less than 4 mmHg after 
surgery, while the criteria of Teehasaenee and Ritch [11] were used to define shallow 
anterior chamber. An intraocular pressure spike was defined as an intraocular pressure on 
the first postoperative day that was greater than or equal to 3 mmHg higher than the level 
observed preoperatively. 
2.2 Statistical analysis 
A Student’s t-test was used to evaluate the continuous variables, while a paired t-test was 
used was used to evaluate the difference in intraocular pressures between the follow-up 
intervals. All t-tests were two-tailed. Categoric variables were evaluated by using the chi-
square test, the Fisher exact test, or the Spearman rank correlation, as appropriate. Results 
were defined as being statistically significant when P < 0.05. 
For the pairing of groups, baseline values for age, sex, BCVA, and prothrombin time-
international normalized ratio (PT-INR) were used for matching. When correlations 
between paired observations were noted, we used the F-test to examine the variances 
between the two populations. 
3. Results 
Baseline 
Patient demographics are summarized in Table 2. No significant differences were found 
between the two subgroups for age, sex, or BCVA in the phacoemulsification alone group 
and the combined phacoemulsification and vitrectomy group. In patients who were 
administered warfarin, mean PT-INR was 1.94 ± 0.77 in the maintenance subgroup and 1.87 
± 0.62 in the discontinuation subgroup in the phacoemulsification alone group (P = 0.3) and 
1.89 ± 0.57 in the maintenance subgroup and 2.23 ± 0.66 in the maintenance subgroup in the 
combined phacoemulsification and vitrectomy group (P = 0.0249). 
3.1 Hemorrhagic and non-hemorrhagic complications 
Phacoemulsification alone group: As seen in Table 3, there were no systemic complications 
or any significant intraoperative bleeding noted for the two subgroups. There were 87 eyes 
(21.6 %) in the maintenance subgroup and 46 eyes (10.9%) in the discontinuation subgroup 
that exhibited subconjunctival hemorrhage of greater than one quadrant (P < 0.0001). On the 
first postoperative day, microscopic hyphema was seen in 26 eyes (6.5%) in the maintenance 
subgroup and in 11 eyes (2.6%) in the discontinuation subgroup (P = 0.0078), whereas no 
apparent hyphema was found in the two subgroups. Within 1 week of the surgical 
procedure, all bleeding had stopped without affecting the visual acuity. There was also no 
vitreous or choroidal/ suprachoroidal hemorrhage found in either of the two subgroups. 
There were 5 posterior capsule rupture and 2 vitreous loss in the maintenance subgroup and 
7 posterior capsule rupture and 3 vitreous loss in the discontinuation subgroup, respectively 
(posterior capsule rupture: P = 0.6; vitreous loss: P = 0.7) (Table 3). No significant differences 
were noted for the incidence of non-hemorrhagic intraoperative complications between the 
two subgroups. 
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Phacoemulsication alone group
 Maintenance subgroup Discontinuation subgroup P 
No.of patients (no. of eyes) 258 (403) 274 (421) - 
Age 74.3±7.7 (46 – 88) 73.7±8.4 (48 – 90) 0.4 
Gender 135 females,  
122 males 
147 females,  
127 males 
0.8 
Best-corrected visual acuity 0.313 (20/64.0) 
(0.01 – 0.8) 
0.326 (20/61.3) 
(0.01 – 0.8) 
- 
LogMAR ± SD 0.505 ± 0.391 0.486 ± 0.393 0.5 
Nuclear sclerosis 2.4 ± 0.8 (1 - 5) 2.3 ± 0.8 (1 - 5) 0.1 
Administration 
Warfarin only 51 (83)  61 (96) 0.7 
Aspirin only 194 (299) 197 (302) 
Both  13 (21) 16 (23) 
PT-INR 1.89±0.56 (1.17–3.54) 1.95±0.58 (1.20-3.47) 0.4 
Duration of warfarin 
administration 
4.2±2.1 (1 -14) 4.5±1.8 (2-12) 0.3 
 
Combined phacoemulsication and vitrectomy group
 Maintenance group Discontinuation group P 
No.of patients (No. of eyes) 36 (36) 33 (33)  
Age 63.8±7.1 (51 – 78) 64.6±7.2 (52– 76) 0.6 
Gender 23 females,  
13 males 
20 females,  
13 males 
0.8 
Epiretinal membrane 22 19 0.8 
Macular hole 14 14 
Best-corrected visual acuity 0.290 (20/68.9) 
(0.08-0.5) 
0.311 (20/64.1) 
(0.1-0.6) 
- 
LogMAR ± SD 0.537 ± 0.216 0.506 ± 0.193 0.5 
Nuclear sclerosis 2.2 ± 0.6 (1 - 4) 2.1 ± 0.7 (1 - 3) 0.5 
Administration 
Warfarin only 7 8 0.7 
Aspirin only 26 22 
Both  3 3 
PT-INR 1.89±0.57 (1.31-3.14) 2.23±0.66 (1.38-3.46) 0.0249 
Duration of warfarin 
administration 
4.1±1.7 (2-8) 4.4±1.6 (2-7) 0.5 
LogMAR ± SD: Log of the minimum angle of resolution ± Standard Deviation 
PT-INR: prothrombin time-international normalized ratio 
Table 2. Demographics of Patients 
Combined phacoemulsification and vitrectomy group: Hyphema, apparent or microscopic, 
was seen on the first postoperative day in 15 eyes (41.7%) in the maintenance subgroup and 
in 3 eyes (45.5%) in the discontinuation subgroup (P = 0.6). Minor postoperative vitreous 
and retinal hemorrhage was found in 3 eyes (7.7%) and 6 eyes (15.4%) in the maintenance 
subgroup and in 2 eyes (5.6%) and 8 eyes (22.2%) in the discontinuation subgroup, 
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respectively (vitreous hemorrhage: P = 0.3; retinal hemorrhage: P = 0.3) (Table 3). Within 1 
month of the surgical procedure, bleeding was not found without affecting the visual acuity. 
There was no vitreous or choroidal/suprachoroidal hemorrhage found in either of the two 
subgroups. No significant difference was found in non-hemorrhagic complications between 
the two subgroups (Table 3). 
 
Phacoemulsification alone group 
 Maintenance 
group 
Discontinuation 
group 
P 
 403 eyes 421 eyes  
Systemic complications
Cerebral events 0 (0.0%) 0 (0.0%) - 
Cardiovascular events 0 (0.0%) 0 (0.0%) - 
Hemorrhagic complications
Subconjunctival hemorrhage 87 (21.6%) 46 (10.9%) < 0.0001 
Hyphema (> 1mm) 0 (0.0%) 0 (0.0%) - 
Microscopic hyphema 26 (6.5%) 11 (2.6%) 0.0078 
Vitreous hemorrhage 0 (0.0%) 0 (0.0%) - 
Retinal hemorrhage 6 (1.4%) 3 (0.7%) 0.3 
Choroidal/suprachoridal 
hemorrhage 
0 (0.0%) 0 (0.0%) - 
Non-hemorrhagic complications
Intraoperative complications    
Early perforation 7 (1.7%) 9 (1.1%) 0.7 
CCC tear 13 (4.0 %) 18 (4.3%) 0.4 
Posterior capsule rupture 5 (1.2%) 7 (1.7%) 0.6 
Vitreous loss 2 (0.4%) 3 (0.3%) 0.7 
Nucleus drop 0 (0.0%) 0 (0.0%) - 
Early postoperative complications 
Hypotony 0 (0.0%) 0 (0.0%) - 
IOP spike 16 (3.9%) 13 (3.1%) 0.5 
Corneal edema 8 (2.0%) 10 (2.4%) 0.7 
Shallow/flat anterior chamber 0 (0.0%) 0 (0.0%) - 
Distorted pupil 2 (0.0%) 3 (0.0%) 0.7 
IOL dislocation 0 (0.0%) 0 (0.0%) - 
Vitreous herniation 0 (0.0%) 0 (0.0%) - 
Retinal detachment 0 (0.0%) 0 (0.0%) - 
Endophthalmitis 0 (0.0%) 0 (0.0%) - 
 
Combined phacoemulsification and vitrectomy group 
 Maintenance 
group 
Discontinuation 
group 
P 
 36 eyes 33 eyes  
Systemic complications
Cerebral events 0 (0.0%) 0 (0.0%)  
Cardiovascular events 0 (0.0%) 0 (0.0%)  
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Hemorrhagic complications
Hyphema (> 1mm) 1 (2.8%) 0 (0.0%) 0.3 
Microscopic hyphema 14 (38.9%) 15 (45.5%) 0.6 
Vitreous hemorrhage 3 (7.7%) 2 (5.6%) 0.3 
Retinal hemorrhage 6 (15.4%) 8 (22.2%) 0.3 
Choroidal/suprachoridal 
hemorrhage 
0 (0.0%) 0 (0.0%) - 
Non-hemorrhagic complications
Intraoperative complications    
Early perforation 0 (0.0%) 0 (0.0%) - 
CCC tear 2 (5.6%) 1 (3.0%) 0.6 
Posterior capsule rupture 0 (0.0%) 0 (0.0%) - 
Vitreous loss 0 (0.0%) 0 (0.0%) - 
Early postoperative complications 
Hypotony 0 (0.0%) 0 (0.0%) - 
IOP spike 4 (11.1%) 2 (6.1%) 0.4 
Corneal edema 0 (0.0%) 0 (0.0%) - 
Shallow/flat anterior chamber 0 (0.0%) 0 (0.0%) - 
Distorted pupil 0 (0.0%) 0 (0.0%) - 
IOL dislocation 0 (0.0%) 0 (0.0%) - 
Retinal detachment 1 (2.8%) 0 (0.0%) 0.3 
Endophthalmitis 0 (0.0%) 0 (0.0%) - 
Table 3. Incidence of hemorrhagic and non-hemorrhagic complications in the 
discontinuation and maintenance group 
3.2 Visual acuity change 
Phacoemulsication alone group: Mean BCVA before and at 1 month postoperative were 
0.312 and 0.917 in the maintenance subgroup and 0.326 and 0.925 in the discontinuation 
subgroup, respectively (Table 4). The mean changes for the LogMAR BCVA during the 1-
month postoperative period were -0.467 ± 0.339 in the maintenance subgroup and -0.453 ± 
0.342 in the discontinuation subgroup. These differences were not significant between the 
two subgroups (P = 0.6) (Table 4). 
Combined phacoemulsification and vitrectomy group: In patients undergoing surgery for 
the treatment of epiretinal membrane, mean BCVA before and at 6 months postoperative 
were 0.337 and 0.757 in the maintenance subgroup and 0.359 and 0.737 in the 
discontinuation subgroup, respectively (Table 4). The mean changes for the LogMAR BCVA 
during the 1-month postoperative period were -0.351 ± 0.173 in the maintenance subgroup 
and -0.312 ± 0.164 in the discontinuation subgroup (P = 0.5) (Table 4). In patients with 
macular hole, all patients had macular hole closure in the two subgroups. Mean BCVA 
before and at 6 months postoperative were 0.229 and 0.774 in the maintenance subgroup 
and 0.257 and 0.796 in the discontinuation subgroup, respectively (Table 4). The mean 
changes for the LogMAR BCVA during the 6-month postoperative period were -0.528 ± 
0.195 in the maintenance subgroup and -0.491 ± 0.216 in the discontinuation subgroup (P = 
0.6) (Table 4). 
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Phacoemulsification alone group 
 Maintenance group Discontinuation 
group 
 
No.of eyes 403 421  
Baseline 
BCVA 0.312 (20/64.0) 0.326 (20/63.3) - 
Mean (LogMAR) ± SD 0.505±0.391 0.486±0.393 0.45 
1day 
BCVA 0.849 (20/23.6) 0.853 (20/23.4) - 
Mean (LogMAR) ± SD 0.071±0.187 0.069±0.181 0.9 
Change of LogMAR -0.434±0.325 -0.415±0.328 0.4 
1 week 
BCVA 0.899 (20/22.3) 0.903 (20/22.1) - 
Mean (LogMAR) ± SD 0.047±0.163 0.044±0.157 0.8 
Change of LogMAR -0.459±0.333 -0.442±0.340 0.5 
1 month 
BCVA 0.917 (20/21.8) 0.925 (20/21.6) - 
Mean (LogMAR) ± SD 0.039±0.155 0.034±0.151 0.6 
Change of LogMAR -0.467±0.339 -0.453±0.342 0.6 
Table 4. A Change of Best-corrected Visual Acuity 
4. Discussion 
In patients who maintained warfarin and/or aspirin treatment, no increase was identified in 
potentially sight-threatening complications in the phacoemulsification group and the 
combined phacoemulsification and vitrectomy group compared with those who 
discontinued the treatment. In patients undergoing phacoemulsification alone, the incidence 
of subconjunctival hemorrhage and microscopic hyphema in the maintenance subgroup was 
significantly higher compared with the discontinuation subgroup; all subconjunctival 
hemorrhage and hyphema in both subgroups were self-limiting and spontaneously resolved 
within one week.  
In patients undergoing combined phacoemulsification and vitrectomy, there was no 
significant difference in hemorrhagic complications between patients with and without 
interruption of anticoagulant and/or antiplatelet therapy. In patients undergoing cataract 
surgery alone, several investigators have demonstrated that the incidence of hemorrhagic 
complications was approximately 9-10% (range 0 to 36.1%, mean 13.0±13.3%) in 
anticoagulated patients without discontinuation of warfarin. Postoperative hemorrhagic 
complications typically consisted of mild hyphemae and subconjunctival hemorrhage, all of 
which were self-limiting and without further clinical consequences. [12-27]. Several studies 
have compared postoperative bleeding in anticoagulant-treated patients with that of 
normally coagulated patients. Even patients with normal coagulation undergoing cataract 
surgery may have postoperative hemorrhage. Patients without warfarin discontinuation 
have an approximately 3-fold greater risk for postoperative bleeding than normally 
anticoagulated patients who have cataract surgery [14,21,23-27]. 
The variance of the incidence of hemorrhagic complications previously reported may result 
from inconsistency of their definition and the duration and methods of their observation 
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[12-27]. Hemorrhagic complication rates may have also been influenced by the anesthestic 
and surgical techniques used. It is difficult to accurately measure risks of local anesthetic 
blockade in anticoagulated patients since anesthetic techniques varied as studies done after 
the late 1990s tended towards use of topical or sub-Tenon anesthesia [21-27], whereas, 
before then, retrobulbar or peribulbar anesthesia had been commonly used [13,15,20,21] 
Retrobulbar hemorrhage is more frequent even when anticoagulation is discontinued prior 
to surgery when compared to normally coagulated patients [27]. Prognosis for visual acuity 
with retrobulbar hemorrhage is generally good, provided an experienced surgeon is present 
to rapidly decompress the eye. However, sub-Tenon block and topical techniques appear 
safer still, and acceptable provided both patients and surgeons are satisfied. In the studies 
after the mid-1990s phacoemulsification was in common use [16,17,21-24,26,27]. Before then, 
the extracapsular extraction technique, which needed a larger wound and caused greater 
tissue injury and bleeding than the phacoemulsification technique, had been employed. [12-
15,17,20]. However, hemorrhagic complication rates did not appear to differ based on 
surgical technique.  
Benzimra et al. showed a significant increase in hemorrhagic and non-hemorrhagic 
complications without discontinuation of continuous antiplatelet medications [27], whereas 
other studies have demonstrated no increase [28-30]. These complications had no significant 
effect on visual improvement [27-30]. 
In this study, patients undergoing vitreous surgery with epiretinal and macular hole in 
combination with phacoemulsification were studied. Even normally coagulated patients 
undergoing vitrectomy have a risk of hemorrhagic complications from other diseases, 
including retinal detachment and proliferative diabetic retinopathy, which were hence 
excluded from this study. In patients without interruption of anticoagulant and/or 
antiplatelet medications, there were 14 microscopic hyphema and 6 retinal hemorrhages, 
whereas 15 microscopic hyphema and 8 retinal hemorrhage were found in patients who 
discontinued the medications. Most of the retinal hemorrhages occurred during the peeling 
of the epiretinal and internal limiting membranes, and hyphema developed from a 
postoperative prone position in patients who underwent macular hole surgery. Several 
investigators demonstrated the incidence of hemorrhagic complications in vitrectomy was 
less than 1% [31-35], the vast majority of which was transient vitreous hemorrhage, which 
was self-limiting and without any significant effect on visual improvement. There was only 
one potentially serious subretinal hemorrhage, which required retinotomy, in patients on 
anticoagulation [34]. Therefore, there has been no reported evidence that perioperative 
continuation of anticoagulant therapy may a deleterious impact on cataract surgery and 
postoperative visual improvement related to either continuation of anticoagulation or 
hemorrhagic complications [1-9]. 
In this study, no systemic complications were noted in patients with and without 
anticoagulant and antiplatelet therapy in the phacoemulsication group and combined 
phacoemulsication and vitrectomy group. Many believe that there may be minimal risk of 
thromboembolism in patients whose anticoagulant therapy is discontinued for surgery [36]. 
Less than a half of reported hospitals continued antiplatelet or anticoagulant regimen at the 
time of surgery in Japan [37], although the majority of the Canadian Society of Cataract and 
Refractive Surgery members reported that they did not stop either warfarin or aspirin for 
cataract surgery during the perioperative period [38]. Current evidence suggests that 
warfarin therapy significantly improves prognosis in patients with atrial fibrillation with 
coexisting cerebrovascular disease, and those with non-tissue prosthetic heart valves [1]. 
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Attempted cessation and recommencement of warfarin therapy may not only reverse 
anticoagulation for unpredictable periods of time but may also expose patients to a transient 
yet dangerous hypercoagulable state [39,40]. The discontinuation of warfarin does not 
prevent thromboembolism. There have been several documented cases of serious embolic 
complications, including deaths, after discontinuing warfarin therapy. Cosgriff reported that 
thromboembolisms occurred in14 of 17 patients (71% of cases) of dental extractions whose 
warfarin therapy was discontinued [41]. In 542 documented cases of discontinuing 
anticoagulant therapy for dental procedures, five cases (0.9%) had serious embolic 
complications, including four deaths [42]. Another study showed that discontinuation of 
anticoagulant therapy did not increase the incidence of thromboemobolitic events, but 
caused it to become serious and to increase the morbidity once the events occur [1]. 
However, in patients with cataract surgery, there was one (2.4%) thromboembolic 
complication in 36 cases of discontinuing anticoagulant treatment [14]. There were none 
(0%) in 208 patients discontinuing anticoagulant therapy whereas two thromboembolisms 
(0.4%) were reported in 524 anticoagulated patients and 15 thromboembolisms (0.08%) in 
18,215 normally coagulated patients [21]. 
This study has important limitations. The study design was non-randomized, and the 
sample size of this study was relatively small and therefore not powered to detect small 
differences. Small sample size also precluded an assessment of safety. A large-scale 
randomized study is required to assess the safety of continuous anticoagulant and 
antiplatelet treatment associated with phacoemulsification alone and in combination with 
vitrectomy. 
In cataract surgery blood vessels likely to cause persistent hemorrhage are unlikely to be 
encountered [6]. Although there is a theoretical risk of hemorrhagic complications after 
cataract surgery in patients at therapeutic levels of anticoagulation, the risk may be greatly 
outweighed by the risk and morbidity of thromboembolism after discontinuation of 
anticoagulant therapy [2-9]. There are several documented cases of serious thromboembolic 
complications, including deaths, in patients after discontinuation of anticoagulant therapy 
[41,42]. Patients receiving anticoagulant therapy who undergo cataract surgery have been 
reported to have more hemorrhagic complications than patients with normal coagulation. 
The vast majority of these complications are self-limiting and without significant effect on 
visual improvement. Ophthalmologists and physicians should collaborate closely in treating 
their patients who are taking anticoagulants, especially to make sure that the patient’s INR 
is within the therapeutic range before cataract surgery [1-9]. Good surgical and anesthetic 
techniques and local measure, including cautery, to control bleeding are also important in 
all patients undergoing intraocular surgery, especially those receiving continuous 
anticoagulant and antiplatelet medications [3-9,23]. 
Although the sample size in each group was small, the current study demonstrated that (1) 
patients undergoing cataract surgery alone who maintained warfarin and/or aspirin 
experienced a significantly higher incidence of subconjunctival hemorrhage and hyphema 
compared with those who discontinued them; and (2) there was no significant difference in 
the incidence of intraoperative and postoperative complications and visual improvement 
between patients with and without interruption of anticoagulant and antiplatelet 
medications in patients undergoing cataract surgery alone and in combination with 
vitrectomy. Future study of a large population is needed to verify these observations. 
However, this information may be clinically valuable when treating patients with cataract 
and long-term administration of anticoagulant or antiplatelet medication. 
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